Literature DB >> 17720775

Expression of HDAC1 and CBP/p300 in human colorectal carcinomas.

Katsuyoshi Ishihama1, Mitsunori Yamakawa, Shuho Semba, Hiroaki Takeda, Sumio Kawata, Seishi Kimura, Wataru Kimura.   

Abstract

BACKGROUND: The histone-modifying enzymes histone deacetylase (HDAC) and histone acetyltransferase (HAT) control gene transcriptional activation and repression in human malignancies. AIMS: To analyse the expression of HDAC/HAT-associated molecules such as HDAC1, CREB-binding protein (CBP) and p300 in human colorectal carcinomas, and investigate the relationship between their expression levels and clinicopathological parameters.
METHODS: Expression levels of HDAC1, CBP, and p300 in human colorectal cancer were investigated by immunohistochemistry. In situ hybridisation (ISH) and reverse transcription (RT)-PCR analyses were also carried out to confirm mRNA expression levels of these genes. Immunoreactivity was evaluated semi-quantitatively using a staining index (SI). The relationships between the SIs and clinicopathological findings were analysed and survival curves were calculated using the Kaplan-Meier method and log-rank tests.
RESULTS: The mean SIs for HDAC1, CBP, and p300 in this series of tumours were much higher than those in normal colonic mucosa. The presence of HDAC1 and CBP mRNAs on colorectal carcinoma cells as well as normal epithelial cells was confirmed by ISH analysis. A marked increase in p300 mRNA levels was detected in a majority of cases by RT-PCR. Among the patients with colorectal cancer, overexpression of p300 (SI>11.9) correlated with a poor prognosis, whereas high CBP expression levels (SI>16.6) indicated long-term survival.
CONCLUSION: Results showed the up-regulation of these three histone-modifying molecules in this series of colorectal cancers and suggested that monitoring of CBP and p300 may assist prediction of the prognosis in patients with colorectal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720775      PMCID: PMC2095491          DOI: 10.1136/jcp.2005.029165

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  39 in total

1.  The language of covalent histone modifications.

Authors:  B D Strahl; C D Allis
Journal:  Nature       Date:  2000-01-06       Impact factor: 49.962

2.  Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines.

Authors:  T Suzuki; H Yokozaki; H Kuniyasu; K Hayashi; K Naka; S Ono; T Ishikawa; E Tahara; W Yasui
Journal:  Int J Cancer       Date:  2000-12-15       Impact factor: 7.396

3.  Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.

Authors:  T Maeda; M Towatari; H Kosugi; H Saito
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

4.  Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.

Authors:  D M Vigushin; S Ali; P E Pace; N Mirsaidi; K Ito; I Adcock; R C Coombes
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

5.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Authors:  V M Richon; T W Sandhoff; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

Review 6.  Histone deacetylase inhibitors as new cancer drugs.

Authors:  P A Marks; V M Richon; R Breslow; R A Rifkind
Journal:  Curr Opin Oncol       Date:  2001-11       Impact factor: 3.645

7.  Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome.

Authors:  T Murata; R Kurokawa; A Krones; K Tatsumi; M Ishii; T Taki; M Masuno; H Ohashi; M Yanagisawa; M G Rosenfeld; C K Glass; Y Hayashi
Journal:  Hum Mol Genet       Date:  2001-05-01       Impact factor: 6.150

8.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Authors:  L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

9.  Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.

Authors:  M S Kim; H J Kwon; Y M Lee; J H Baek; J E Jang; S W Lee; E J Moon; H S Kim; S K Lee; H Y Chung; C W Kim; K W Kim
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

10.  Butyrate production from dietary fibre and protection against large bowel cancer in a rat model.

Authors:  A McIntyre; P R Gibson; G P Young
Journal:  Gut       Date:  1993-03       Impact factor: 23.059

View more
  61 in total

Review 1.  Modulating the wnt signaling pathway with small molecules.

Authors:  Freddi Huan Tran; Jie J Zheng
Journal:  Protein Sci       Date:  2017-02-11       Impact factor: 6.725

2.  Epigenetic mechanisms underlying diet-sourced compounds in the prevention and treatment of gastrointestinal cancer.

Authors:  Rebecca W Knackstedt; Vondina R Moseley; Michael J Wargovich
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

3.  Selective small molecule targeting β-catenin function discovered by in vivo chemical genetic screen.

Authors:  Jijun Hao; Ada Ao; Li Zhou; Clare K Murphy; Audrey Y Frist; Jessica J Keel; Curtis A Thorne; Kwangho Kim; Ethan Lee; Charles C Hong
Journal:  Cell Rep       Date:  2013-09-05       Impact factor: 9.423

Review 4.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

5.  Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer.

Authors:  Yina Gao; Jingshu Geng; Xuan Hong; Jiping Qi; Yang Teng; Yang Yang; Di Qu; Gongyan Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

6.  The F-box protein beta-TrCp1/Fbw1a interacts with p300 to enhance beta-catenin transcriptional activity.

Authors:  Erin A Kimbrel; Andrew L Kung
Journal:  J Biol Chem       Date:  2009-03-17       Impact factor: 5.157

7.  Interleukin-4 activates androgen receptor through CBP/p300.

Authors:  Soo Ok Lee; Jae Yeon Chun; Nagalakshmi Nadiminty; Wei Lou; Siting Feng; Allen C Gao
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

8.  Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

Authors:  Annunziata Gloghini; Daniela Buglio; Noor M Khaskhely; Georgios Georgakis; Robert Z Orlowski; Sattva S Neelapu; Antonino Carbone; Anas Younes
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

9.  Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line.

Authors:  Jennifer S Waby; Haridasan Chirakkal; ChenWei Yu; Gareth J Griffiths; Roderick S P Benson; Colin D Bingle; Bernard M Corfe
Journal:  Mol Cancer       Date:  2010-10-15       Impact factor: 27.401

10.  Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.

Authors:  Junko Suzuki; Yunn-Yi Chen; Gary K Scott; Sandy Devries; Koei Chin; Christopher C Benz; Frederic M Waldman; E Shelley Hwang
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.